MRC Human Immunology Unit, and Oxford NIHR Biomedical Research Centre, University of Oxford, UK.
MRC Human Immunology Unit, University of Oxford, UK.
Curr Opin Immunol. 2019 Aug;59:121-129. doi: 10.1016/j.coi.2019.07.006. Epub 2019 Aug 21.
T cell receptor (TCR) recognition of antigens presented by relatively non-polymorphic MHC-like molecules is emerging as a significant contributor to health and disease. These evolutionarily ancient pathways have been inappropriately labelled 'non-conventional' because their roles were discovered after viral-specific peptide presentation by polymorphic MHC class I molecules. We suggest that these pathways are complementary to mainstream peptide presentation. HLA-E, CD1 and MR1 can present diverse self and foreign antigens to TCRs and therefore contribute to tissue homeostasis, pathogen defence, inflammation and immune responses to cancer. Despite presenting different classes of antigens, they share many features and are under common selective pressures. Through understanding their roles in disease, therapeutic manipulation for disease prevention and treatment should become possible.
T 细胞受体 (TCR) 识别相对非多态 MHC 样分子呈递的抗原,正成为健康和疾病的重要贡献者。这些进化古老的途径被不恰当地标记为“非传统”,因为它们的作用是在多态 MHC 类 I 分子呈递病毒特异性肽之后才被发现的。我们认为这些途径与主流肽呈递相辅相成。HLA-E、CD1 和 MR1 可以将不同的自身和外来抗原呈递给 TCR,从而有助于组织稳态、病原体防御、炎症和对癌症的免疫反应。尽管它们呈现不同类别的抗原,但它们具有许多共同的特征,并受到共同的选择压力。通过了解它们在疾病中的作用,应该有可能进行治疗干预以预防和治疗疾病。